Abstract
Familial hypercholesterolemia (FH) is a genetic disorder characterized by elevated low-density lipoprotein (LDL) cholesterol and premature cardiovascular disease, with a prevalence of approximately 1 in 200–500 for heterozygotes in North America and Europe. Monogenic FH is largely attributed to mutations in the LDLR, APOB, and PCSK9 genes. Differential diagnosis is critical to distinguish FH from conditions with phenotypically similar presentations to ensure appropriate therapeutic management and genetic counseling. Accurate diagnosis requires careful phenotyping based on clinical and biochemical presentation, validated by genetic testing. Recent investigations to discover additional genetic loci associated with extreme hypercholesterolemia using known FH families and population studies have met with limited success. Here, we provide a brief overview of the genetic determinants, differential diagnosis, genetic testing, and counseling of FH genetics.
Original language | English |
---|---|
Journal | Current Atherosclerosis Reports |
Volume | 17 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2015 |
Externally published | Yes |
Keywords
- Apolipoprotein B (APOB)
- Autosomal recessive hypercholesterolemia (ARH)
- Cascade testing
- Cerebrotendinous xanthomatosis (CTX)
- Cholesterol ester storage disease (CESD)
- Familial defective apolipoprotein B-100 (FDB)
- Familial hypercholesterolemia (FH)
- Genetic counseling (GC)
- LDL receptor adapter protein 1 (LDLRAP1)
- Low-density lipoprotein receptor (LDLR)
- Penetrance
- Proprotein convertase subtilisin/kexin type 9 (PCSK9)
- Sitosterolemia